Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Front-line combination treatments in GU malignancies: How do we decide?

Hormone-sensitive metastatic prostate cancer

Date

03 Dec 2022

Session

Front-line combination treatments in GU malignancies: How do we decide?

Topics

Tumour Site

Prostate Cancer

Presenters

Nobuaki Matsubara

Authors

N. Matsubara

Author affiliations

Medical Oncology Department, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

03 Dec 2022

Renal cell carcinoma (RCC)

Presenter: Lisa Pickering

Session: Front-line combination treatments in GU malignancies: How do we decide?

Resources:

Slides

Webcast

03 Dec 2022

Urothelial cancer

Presenter: Enrique Grande Pulido

Session: Front-line combination treatments in GU malignancies: How do we decide?

Resources:

Slides

Webcast

03 Dec 2022

Q&A and discussion

Presenter: Masatoshi Eto

Session: Front-line combination treatments in GU malignancies: How do we decide?

Resources:

Slides

Webcast